Risk Management Committee Report Governance The RMC meetings were attended by among others, the Senior Management of the Group; Group Head, Risk Management & Compliance; Group Head, Internal Audit; Group Head, Medical & Quality; and Group Head, Branding Strategy & Environmental Social Governance to brief the RMC on agenda items of the RMC meetings. Minutes of the RMC meetings would be circulated to all members for comments and the decisions made by the RMC would be communicated to the relevant process owners for action. At the Board meetings, the Chairman of the RMC would provide a report highlighting pertinent issues, significant points of the decisions and recommendations made by the RMC to the Board and matters reserved for the Board’s approval, if any. Summary of Activities During the financial year, the RMC carried out the following key activities: Enterprise Risk Management 1. Reviewed the Group’s consolidated Enterprise Risk Management (ERM) reports, including the progress of the ERM transformation, the ERM reports of the respective operating divisions, which covered the ERM reporting status, risk profile, risk priorities and risk mitigation plans to ensure the key risks that arise with the developments in the operating environment are effectively managed; 2. Reviewed and recommended to the Board for approval the updated ERM Policy; 3. Reviewed and recommended to the Board for approval the Group Business Resilience Policy; Information Technology Risk Management 4. Reviewed the reports pertaining to Information Technology (IT) risk universe, which covered, among others, key IT risks and residual risk profile and cybersecurity threat report, aiming to identify and mitigate any potential IT threats which may impact the IT systems in the respective units in the Group; Bribery and Corruption Risk Management 5. Reviewed the Group’s anti-bribery and corruption risk reports, including the risk profile, key controls and mitigation action plans against possible bribery and corruption, and incident reporting in line with the Group’s Anti-Bribery and Corruption (ABC) Policy; 6. Reviewed and recommended to the Board for approval the updated ABC Policy; 7. Reviewed and recommended to the Board for approval the Gift, Hospitality, Donation and Sponsorship Policy; Medical Quality and Clinical Quality Updates 8. Reviewed the reports on Medical Quality and Clinical Quality Updates, which encompassed the following: (i) clinical quality indicators of the Group’s operating divisions in Malaysia, Singapore, India, Hong Kong, Türkiye and Brunei with the key objective of monitoring and assessing the clinical performance of hospitals so as to facilitate continuous quality improvement and benchmarking; (ii) action plans/initiatives undertaken to drive quality improvement activities; (iii) trend of serious reportable events which highlighted problem areas in clinical performance and opportunities for improvement; (iv) the Group’s medico-legal litigation cases; (v) clinical assurance framework; (vi) clinical audit; Sustainability 9. Discussed the sustainability roadmap and monitored the progress of the overall sustainability short, mid and long term strategy and action plans; 10. Reviewed and recommended to the Board for approval the Sustainability Report for inclusion in the Annual Report 2022; 11. Deliberated on key environmental, social and governance (ESG) risks and progress of risk mitigation plans; 12. Reviewed the sustainability updates which included the progress against IHH’s 2023-2025 sustainability goals and other sustainability metrics; 13. Kept abreast with the evolving ESG reporting landscape, including launch of new sustainability disclosure standards by the International Sustainability Standards Board (ISSB); and Other Activities 14. Reviewed and recommended to the Board for approval the RMC Report, as well as Statement on Risk Management and Internal Control for inclusion in the Annual Report 2022. IHH Healthcare Berhad 110
RkJQdWJsaXNoZXIy NDgzMzc=